<DOC>
	<DOCNO>NCT02224066</DOCNO>
	<brief_summary>A high platelet reactivity patient severe symptomatic Aortic Stenosis ( AS ) select TAVI ( Transcatheter aortic valve implantation ) procedure demonstrate previously , use double antiaggregation therapy ( DAPT ) Clopidogrel Acetylsalicylic acid ( ASA ) achieve consistent adequate suppression platelet reactivity . The purpose study evaluate efficacy ticagrelor alone versus DAPT clopidogrel aspirin suppression high platelet reactivity follow TAVI .</brief_summary>
	<brief_title>Platelet Reactivity After TAVI : A Multicenter Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>For inclusion study subject fulfill follow criterion : 1 . Provision inform consent prior study specific procedure . 2 . Adult patient ( 18 year ) ability understand accept participation clinical trial . 3 . Patients degenerative symptomatic severe AS accept TAVI evaluation Heart Team center . 4 . Patients participate clinical trial research study ( registry allow ) . Subjects enter study follow exclusion criterion fulfil : 1 . Recent stroke &lt; 14 day prior TAVI , nonrevascularized severe coronary carotid artery disease ( &gt; 70 % stenosis ) life expectancy &lt; 12 month 2 . Patients chronic oral anticoagulation 3 . Patients proven allergy aspirin , clopidogrel ticagrelor 4 . Patients TAVI undergo regimen single dual antiplatelet therapy 3 month due new postTAVI medical indication 5 . Known pregnancy breastfeed 6 . Concomitant oral intravenous therapy potent inhibitor cytochrome P450 3A ( CYP3A ) suspend course study . Medications consider potent inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin ( erythromycin astromicin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , daily liter grapefruit juice . 7 . Thrombocytopenia ( &lt; 50,000 platelet U/L ) well document clinically relevant . 8 . Patients document moderate severe hepatic insufficiency 9 . Any condition may put patient risk influence outcome trial 10 . Patients previously randomize trial another clinical trial investigational product device past 30 day . 11 . Patients attend follow visit schedule study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Aortic stenosis</keyword>
	<keyword>TAVI</keyword>
	<keyword>TAVR</keyword>
	<keyword>Transcatheter aortic valve implantation</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Antiplatelet reactivity</keyword>
</DOC>